Ovarian Rejuvenation Using Platelet Rich Plasma (PRP) & Autologous Tissue Stromal Vascular Fraction (tSVF) and Cell Enriched tSVF
Re-establishment of Ovarian Hormonal Function, Delay of Menopause, or Reversal of Early Menopause With High Density (HD PRP), tSVF + PRP, or Cell Enriched tSVF + PRP by Ultrasound Guided Ovarian Injection
Sponsor: Black Tie Medical, Inc.
This PHASE1 trial investigates Hormone Disturbance and Ovarian Failure and is currently ongoing. Black Tie Medical, Inc. leads this study, which shows 8 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE1
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Sep 2022 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
-
Mar 2021 — Sep 2022 [monthly]
Active Not Recruiting PHASE1
▶ Show 3 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
-
Jul 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Black Tie Medical, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Colchester, United States